CANbridge Pharmaceuticals Inc. (HKG:1228)

CANbridge Pharmaceuticals Cash Flow Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-442.62	-378.84	-483.48	-1,077
Depreciation & Amortization	27.16	28.34	21.92	15.67
Other Amortization	0.09	0.12	0.06	0.03
Loss (Gain) From Sale of Assets	-2.23	2.01	1.25	-9.73
Asset Writedown & Restructuring Costs	89.41	4.01	-	-
Stock-Based Compensation	7.69	19.92	26.82	30.51
Other Operating Activities	15.63	18.13	33.5	430.43
Change in Accounts Receivable	14.64	-12.17	-9.91	-2.1
Change in Inventory	0.88	1.04	3.62	-12.9
Change in Accounts Payable	165.09	90.51	63.93	-3.11
Change in Other Net Operating Assets	1.87	-51.3	61.31	41.12
Operating Cash Flow	-122.4	-278.23	-280.98	-587.07
Capital Expenditures	-0.11	-5.14	-15.2	-5.09
Sale of Property, Plant & Equipment	0.03	-	-	-
Sale (Purchase) of Intangibles	-	-35.33	-0.14	131.18
Sale (Purchase) of Real Estate	14.01	14.01	-	-
Other Investing Activities	-	-0.38	-19.45	-
Investing Cash Flow	13.93	-26.86	-34.79	126.09
Long-Term Debt Issued	27.93	19.8	38.63	20.76
Long-Term Debt Repaid	-45.08	-45.77	-43.31	-32.08
Net Debt Issued (Repaid)	-17.15	-25.97	-4.68	-11.32
Issuance of Common Stock	0.04	0.08	0.03	563.8
Other Financing Activities	-1.45	-2.13	-16.06	-33.07
Financing Cash Flow	-18.57	-28.02	-20.7	854.31
Foreign Exchange Rate Adjustments	0.05	6.85	41.81	-8.32
Net Cash Flow	-126.99	-326.26	-294.66	385.01
Free Cash Flow	-122.5	-283.38	-296.18	-592.16
Free Cash Flow Margin	-143.94%	-275.47%	-375.04%	-1900.31%
Free Cash Flow Per Share	-0.29	-0.67	-0.70	-6.28
Cash Interest Paid	1.45	1.49	2.17	1.38
Levered Free Cash Flow	16.48	-202.09	-142.04	-207.98
Unlevered Free Cash Flow	21.84	-196.5	-137.75	-206.05
Change in Working Capital	182.48	28.08	118.95	23.02

Source: S&P Global Market Intelligence. Standard template. Financial Sources.